Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 : a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. / Sulzgruber, Patrick; Wassmann, Sven; Semb, Anne Grete; Doehner, Wolfram; Widimsky, Petr; Gremmel, Thomas; Kaski, Juan Carlos; Savarese, Gianluigi; Rosano, Giuseppe M C; Borghi, Claudio; Kjeldsen, Keld; Torp-Pedersen, Christian; Schmidt, Thomas Andersen; Lewis, Basil S; Drexel, Heinz; Tamargo, Juan; Atar, Dan; Agewall, Stefan; Niessner, Alexander.

I: European heart journal. Cardiovascular pharmacotherapy, Bind 5, Nr. 3, 2019, s. 171-180.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Sulzgruber, P, Wassmann, S, Semb, AG, Doehner, W, Widimsky, P, Gremmel, T, Kaski, JC, Savarese, G, Rosano, GMC, Borghi, C, Kjeldsen, K, Torp-Pedersen, C, Schmidt, TA, Lewis, BS, Drexel, H, Tamargo, J, Atar, D, Agewall, S & Niessner, A 2019, 'Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke', European heart journal. Cardiovascular pharmacotherapy, bind 5, nr. 3, s. 171-180. https://doi.org/10.1093/ehjcvp/pvz016

APA

Sulzgruber, P., Wassmann, S., Semb, A. G., Doehner, W., Widimsky, P., Gremmel, T., Kaski, J. C., Savarese, G., Rosano, G. M. C., Borghi, C., Kjeldsen, K., Torp-Pedersen, C., Schmidt, T. A., Lewis, B. S., Drexel, H., Tamargo, J., Atar, D., Agewall, S., & Niessner, A. (2019). Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. European heart journal. Cardiovascular pharmacotherapy, 5(3), 171-180. https://doi.org/10.1093/ehjcvp/pvz016

Vancouver

Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T o.a. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. European heart journal. Cardiovascular pharmacotherapy. 2019;5(3):171-180. https://doi.org/10.1093/ehjcvp/pvz016

Author

Sulzgruber, Patrick ; Wassmann, Sven ; Semb, Anne Grete ; Doehner, Wolfram ; Widimsky, Petr ; Gremmel, Thomas ; Kaski, Juan Carlos ; Savarese, Gianluigi ; Rosano, Giuseppe M C ; Borghi, Claudio ; Kjeldsen, Keld ; Torp-Pedersen, Christian ; Schmidt, Thomas Andersen ; Lewis, Basil S ; Drexel, Heinz ; Tamargo, Juan ; Atar, Dan ; Agewall, Stefan ; Niessner, Alexander. / Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 : a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. I: European heart journal. Cardiovascular pharmacotherapy. 2019 ; Bind 5, Nr. 3. s. 171-180.

Bibtex

@article{caf43a66906c44679e656cb33f1c839c,
title = "Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke",
abstract = "Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.",
author = "Patrick Sulzgruber and Sven Wassmann and Semb, {Anne Grete} and Wolfram Doehner and Petr Widimsky and Thomas Gremmel and Kaski, {Juan Carlos} and Gianluigi Savarese and Rosano, {Giuseppe M C} and Claudio Borghi and Keld Kjeldsen and Christian Torp-Pedersen and Schmidt, {Thomas Andersen} and Lewis, {Basil S} and Heinz Drexel and Juan Tamargo and Dan Atar and Stefan Agewall and Alexander Niessner",
note = "Published on behalf of the European Society of Cardiology. All rights reserved. {\textcopyright} The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.",
year = "2019",
doi = "10.1093/ehjcvp/pvz016",
language = "English",
volume = "5",
pages = "171--180",
journal = "European Heart Journal - Cardiovascular Pharmacotherapy",
issn = "2055-6837",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1

T2 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

AU - Sulzgruber, Patrick

AU - Wassmann, Sven

AU - Semb, Anne Grete

AU - Doehner, Wolfram

AU - Widimsky, Petr

AU - Gremmel, Thomas

AU - Kaski, Juan Carlos

AU - Savarese, Gianluigi

AU - Rosano, Giuseppe M C

AU - Borghi, Claudio

AU - Kjeldsen, Keld

AU - Torp-Pedersen, Christian

AU - Schmidt, Thomas Andersen

AU - Lewis, Basil S

AU - Drexel, Heinz

AU - Tamargo, Juan

AU - Atar, Dan

AU - Agewall, Stefan

AU - Niessner, Alexander

N1 - Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

PY - 2019

Y1 - 2019

N2 - Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

AB - Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

U2 - 10.1093/ehjcvp/pvz016

DO - 10.1093/ehjcvp/pvz016

M3 - Journal article

C2 - 31119266

VL - 5

SP - 171

EP - 180

JO - European Heart Journal - Cardiovascular Pharmacotherapy

JF - European Heart Journal - Cardiovascular Pharmacotherapy

SN - 2055-6837

IS - 3

ER -

ID: 234147358